IFOM FONDAZIONE ST FIRC DI ONCOLOGIA MOLECOLARE has a total of 35 patent applications. It increased the IP activity by 700.0%. Its first patent ever was published in 2005. It filed its patents most often in EPO (European Patent Office), United States and Australia. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are YUN CHAE OK, ONCOLYS BIOPHARMA INC and INDEX PHARMACEUTICALS AB.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 8 | |
#2 | United States | 7 | |
#3 | Australia | 6 | |
#4 | WIPO (World Intellectual Property Organization) | 3 | |
#5 | Brazil | 2 | |
#6 | Canada | 2 | |
#7 | China | 2 | |
#8 | Republic of Korea | 2 | |
#9 | Mexico | 2 | |
#10 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Organic fine chemistry | |
#5 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Microorganisms | |
#3 | Medical preparations | |
#4 | Measuring microorganism processes | |
#5 | Peptides | |
#6 | Microbiology | |
#7 | Enzymes | |
#8 | Analysing materials | |
#9 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Rossiello Francesca | 11 |
#2 | D'Adda Di Fagagna Fabrizio | 9 |
#3 | Aguado Julio | 8 |
#4 | Raucci Franca | 6 |
#5 | Longo Valter | 6 |
#6 | Jones-Weinert Corey | 4 |
#7 | Samadi Shams Sara | 3 |
#8 | Li Qingsen | 3 |
#9 | Francia Sofia | 3 |
#10 | Costanzo Vincenzo | 3 |
Publication | Filing date | Title |
---|---|---|
WO2020245213A1 | Hect e3 ligase inhibitors and uses thereof | |
EP3601530A1 | Method of generating 2 cell-like stem cells | |
US2019390152A1 | Cell stretching device | |
EP3374507A1 | Crispr-cas sgrna library | |
AU2016328683A1 | New therapeutic strategies against blood cancer | |
BR112018001782A2 | oligonucleotide for use in the treatment and / or prevention of a disease comprising alternative telomere elongation, oligonucleotide for use in the treatment and / or prevention of a noncancerous condition associated with telomere dysfunction and pharmaceutical composition | |
EP3650546A1 | Therapeutic oligonucleotides | |
BR112016023519A2 | wnt / ß-catenin signaling inhibitor, pharmaceutical composition and method of treating and / or preventing a pathology defined by vascular malformation | |
EP2847332A1 | Rna products and uses thereof | |
AU2011347327A1 | uPAR-antagonists and uses thereof |